Press releases
- Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
- Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
- Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
- Cybin Announces Streamlined Clinical Alignment
- Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
- Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
- Cybin to Host Virtual R&D Day on February 28, 2023
- Cybin Announces Promising Results from Sponsored Kernel Flow® Feasibility Study Measuring Psychedelic Effects on the Brain
- Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004
- Cybin Outlines Upcoming Priorities and Milestones for its Clinical Development Programs
More ▼
Key statistics
As of last trade, Cybin Inc (R7E1:DUS) traded at 0.3404, 42.55% above the 52 week low of 0.2388 set on Dec 19, 2022.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.3404 |
---|---|
High | 0.3404 |
Low | 0.3404 |
Bid | 0.3273 |
Offer | 0.3511 |
Previous close | 0.3362 |
Average volume | 2.78k |
---|---|
Shares outstanding | 191.14m |
Free float | 147.76m |
P/E (TTM) | -- |
Market cap | 93.66m CAD |
EPS (TTM) | -0.2904 CAD |
Data delayed at least 15 minutes, as of Mar 29 2023 07:11 BST.
More ▼